King Pharmaceuticals repays $102.1 million of revolver borrowings

By Sara Rosenberg

New York, Aug. 6 - King Pharmaceuticals Inc. repaid $102.1 million of its revolving credit facility during the second quarter, according to a 10-Q filed with the Securities and Exchange Commission on Thursday.

The repayment was $64.8 million in excess of that required by the terms of the revolver.

As of June 30, the availability under the revolver was reduced to $355.1 million and the remaining undrawn commitment totaled about $61.3 million.

King is a Bristol, Tenn.-based prescription pharmaceutical products and animal health products company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.